Dr Loskog is the CEO/CSO of Lokon Pharma and a Professor of immunotherapy at Uppsala University in Sweden. She is a scientific advisor th the venture capital company Nexttobe and a board member of several of their portfolio companies as well as of Medivir (Publ). Dr Loskog did her postdoc at Baylor College of Medicine, Texas, and her research focuses to develop tumor microenvironment gene engineering viral vectors for the treatment of cancer.

Dr. Soria is a scientist and entrepreneur with deep expertise in cancer biology, DNA repair and drug discovery. After obtaining his PhD from the University of Buenos Aires and training at Erasmus Medical Center in the Netherlands, he conducted postdoctoral work at Institut Curie in France. Since establishing his own lab in 2014, he has focused on therapeutic targets and synthetic lethality, fostering strategic collaborations with industry leaders such as Novartis and GSK. In 2020, Dr. Soria co-founded OncoPrecision. The company leverages proprietary ex-vivo screening technologies—utilizing both patient-derived and healthy donor cells—to develop next-generation ADCs and BsAbs for precision oncology.

Amer Alghabban currently serves as R&D Quality Regulatory Authority Inspection Management Lead at Bristol Myers Squibb, where he leads inspection strategy and regulatory compliance across global clinical development programmes. A clinical pharmacologist by training, he brings over 35 years' experience spanning pharma and biotech Clinical Research, and Development, pharmacovigilance (PV), and regulatory authority (RA) roles at the MHRA, where he served as the MHRA’s Pharmacovigilance Compliance and Quality Officer.

Amer has led global inspection-readiness initiatives and successfully managed more than 180 RA inspections across GCP and PV. As an IRCA-certified Lead Auditor, he has 25 years' auditing experience across GCP, GVP, GCLP, GLP, and GDP. He is the author of the Dictionary of Pharmacovigilance and the Pharmaceutical Medicine Dictionary, as well as several articles in peer-reviewed journals including the Journal for Clinical Studies, British Journal of Cancer, and Clinical Trials Arena. He previously served as Assistant Medical Editor for 11 clinical journals. He has delivered GxP training worldwide and has been an invited speaker at over 200 international conferences.

His previous leadership roles include Vice President, GxP QA, Compliance & Training at Karyopharm Therapeutics; Director and Global Head of R&D Quality & Training at Merck Serono; and Global Head of GxP QA at Arpida AG.

Paloma Moraga Alapont is a Project Manager for international clinical trials and European projects at the Clinical Trials Unit of La Paz University Hospital. She holds a degree in Biotechnology, two master's degrees in Biomedical Research and Clinical Trials, PMP certificated by the American project management institute and has a PhD in Pharmacology and Physiology. Her research focuses on factors influencing subject recruitment in early-phase clinical trials, as well as on potential tools to facilitate and optimize recruitment processes. 

With 13 years of experience in clinical research, Sarah has developed a strong focus on patient engagement throughout all stages of clinical development. She has spent 9 years at Parexel, where she continues to play a key role in strategic service development, patient engagement tactics, decentralized clinical trial services, and training programs. 

Sarah specializes in patient-led clinical research, working closely with advocacy groups and patient communities to improve clinical trial access, education, and experiences for patients, their families, and industry partners. She has successfully supported patient engagement across a variety of therapeutic areas, including Oncology, Endocrinology, Pediatric, Immunology, Dermatology, Ophthalmology, and Neuroscience.

Sarah holds a BA Honors Degree in Journalism and is dedicated to improving the clinical trial journey for patients and stakeholders. 

Eva Bretschneider has led Patient Engagement Strategy at Bayer AG since 2020, with global responsibility for driving patient-centered partnerships and external relations across the healthcare community. She developed and implemented Bayer’s first company‑wide integrated global patient  engagement strategy and built a future‑ready operating model that strengthens patient focus and maximizes asset value. Eva leads Patient Engagement Strategy within the Global Medical &  Evidence Cluster, delivering measurable outcomes through strategic stakeholder engagement and integrated global programs.

A passionate communicator and strategic advisor for more than 15 years, Eva is known for  combining visionary thinking with empathetic leadership to navigate high‑pressure environments, drive continuous improvement, and foster inclusive, cross‑functional collaboration. She represents Bayer on EFPIA’s Patient Think Tank and on the Patient Engagement Open Forum Program  Committee, collaborates with EUPATI and other transnational organizations, and participates in research consortia to create fit‑for‑purpose frameworks for patient‑centered care.

Eva holds a Master’s degree in Communications and Political Sciences from the Free University  of Berlin. Before her current role she led external stakeholder initiatives in healthy aging and  benefit‑risk education, served as global media spokesperson, and designed multi‑stakeholder  public health campaigns and crisis preparedness programs. She builds agile, multi‑stakeholder programs that ensure the voice of patients and care partners is integral to every decision.

Clarke Carlisle is a highly intelligent footballer known for his charitable work outside of the professional sport he had played for years, and is now a well-recognised radio and television presenter.

Clarke Carlisle played football for QPR, Burnley, Blackpool, and Watford to name a few and won promotions with two clubs and played at Wembley Stadium. After over 500 appearances he retired at the end of the 2013 season.

Clarke presented two acclaimed documentaries for the BBC Football’s Suicide Secret and “Is Football Racist?” for the BBC and wrote a book about his career A Footballer’s Life.

What Clarke did not realise was that for the last 13 years of his playing career he had been suffering from Complex Depressive Disorder. It was only after two suicide attempts that he was admitted to psychiatric hospital, where he finally received an accurate diagnosis.  

Since then he has set up the Clarke Carlisle Foundation for Dual Diagnosis. Dual Diagnosis is the condition of suffering from a mental illness and a substance abuse problem at the same time, and Clarke and his team are working towards opening a facility to provide treatment for all those who suffer from Dual Diagnosis. Clarke is an ambassador for the mental health charity Mind, and the Premier League Kick It Out Campaign which promotes inclusion and equality in football.  

Carolina de la Fuente is Associate Director, Country Operations Functional Process Expert at Alexion Pharmaceuticals, AstraZeneca Rare Disease, based in Spain. With more than 24 years in clinical research, she has worked as a CRA, trainer, and manager, building patient‑first, scalable operational processes that improve quality and speed in global studies. Prior to Alexion, she served as Senior Clinical Trial Manager at leading CROs including PRA and ICON, overseeing multi‑country trials across cardiology, infectious diseases, neuroscience, and pediatrics, and partnering closely with sites and sponsors to reduce burden and enhance participation. 

Carolina is the industry co‑chair of EU‑X‑CT, a pan‑European initiative enabling cross‑border clinical trial participation so patients can access studies regardless of geography. Her focus spans end‑to‑end trial delivery, site and country enablement, process optimization, and cross‑functional collaboration—always anchored in the lived experience of patients and caregivers.

She holds a BSc in Medical Biochemistry from King’s College London and an MSc in Molecular and Cellular Biology from Heidelberg University in Germany. 

Carolina’s purpose is to serve the rare disease community by helping bring better treatments, faster, to all patients—wherever they are in the world.

Alex Edwards joined Parkinson's UK in 2022 as the Research Participation and Engagement Manager, leading the charity's research participation programme. Drawing on her background in science communication, she works alongside people affected by Parkinson's, healthcare professionals and researchers to improve access and reduce barriers to participation.

Alex also works on the charity's Race Equality in Research programme, developing and implementing initiatives that aim to improve representation in Parkinson’s research. As part of this work, she pioneered an online support group with and for people affected by Parkinson's from global majority backgrounds.